🇺🇸 ABBV — AbbVie Inc.

Healthcare Compra
← Volver

Precio actual

256,46 USD

Máx. histórico

267,47

37 días

Caída desde máximo

-4,12%

Rango 52 semanas

190,75 – 267,47

Variación hoy

-1,44%

Cierre anterior

260,21

Rango de hoy

255,61 – 258,91

Volumen hoy

4.701.126

Información
Nombre completo
AbbVie Inc.
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
57.000
PER ⓘ
72,45 (puede no estar actualizado)
Dividend yield
2,70% (puede no estar actualizado)
Precio objetivo analistas
276,59 USD (puede no estar actualizado)
Primera cotización
02/01/2013
Precio actualizado
hace 1 día
Sobre la empresa

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Dividendos repartidos Total últimos 12 meses: 6,8300 USD · Yield: 2,66%
Fecha de pago Importe por participación
15/07/2026 1,7300 USD
15/04/2026 1,7300 USD
16/01/2026 1,7300 USD
15/10/2025 1,6400 USD
15/07/2025 1,6400 USD
15/04/2025 1,6400 USD
15/01/2025 1,6400 USD
15/10/2024 1,5500 USD
15/07/2024 1,5500 USD
12/04/2024 1,5500 USD
12/01/2024 1,5500 USD
12/10/2023 1,4800 USD
13/07/2023 1,4800 USD
13/04/2023 1,4800 USD
12/01/2023 1,4800 USD
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
26/02/2014 49,95 50,97 49,93 50,74 +0,04% 2,08% 5.710.700
25/02/2014 50,93 51,13 50,50 50,72 -0,26% 1,24% 5.425.000
24/02/2014 51,01 51,56 50,83 50,85 -0,37% 1,43% 5.693.000
21/02/2014 51,82 51,97 51,01 51,04 -1,58% 1,85% 5.842.700
20/02/2014 51,19 52,11 50,73 51,86 +1,31% 2,70% 6.078.900
19/02/2014 51,17 51,86 50,64 51,19 -0,52% 2,38% 5.242.800
18/02/2014 50,64 51,56 50,56 51,46 +1,44% 1,97% 4.984.900
14/02/2014 50,56 50,91 50,17 50,73 +0,75% 1,46% 4.118.700
13/02/2014 50,30 50,52 49,88 50,35 -0,42% 1,27% 4.946.000
12/02/2014 49,63 50,93 49,59 50,56 +1,81% 2,70% 6.534.500
11/02/2014 49,41 49,97 49,04 49,66 +0,22% 1,88% 7.217.600
10/02/2014 48,75 50,19 48,72 49,55 +1,35% 3,02% 7.907.500
07/02/2014 48,00 49,03 47,66 48,89 +2,00% 2,85% 6.979.500
06/02/2014 47,89 48,18 47,45 47,93 +0,42% 1,52% 4.957.800
05/02/2014 47,76 48,07 47,16 47,73 -0,46% 1,91% 6.987.100
04/02/2014 47,18 47,97 46,95 47,95 +1,27% 2,16% 9.606.100
03/02/2014 49,40 49,49 47,06 47,35 -3,82% 4,92% 10.314.600
31/01/2014 49,94 50,55 49,07 49,23 +1,90% 2,96% 12.863.500
30/01/2014 47,97 48,88 47,90 48,31 +1,47% 2,04% 7.669.500
29/01/2014 47,15 47,84 46,98 47,61 -0,17% 1,82% 7.608.500
28/01/2014 47,08 48,47 47,08 47,69 +1,84% 2,95% 12.298.600
27/01/2014 47,79 47,83 46,42 46,83 -2,01% 2,95% 10.749.800
24/01/2014 48,42 49,10 47,77 47,79 -2,21% 2,75% 9.197.900
23/01/2014 48,74 49,06 48,39 48,87 -0,43% 1,37% 7.270.500
22/01/2014 49,98 50,00 48,62 49,08 -1,84% 2,76% 8.181.700
21/01/2014 50,26 50,92 49,91 50,00 -0,12% 2,01% 5.823.000
17/01/2014 50,64 50,66 50,01 50,06 -0,87% 1,28% 8.606.800
16/01/2014 50,10 50,62 50,02 50,50 +0,78% 1,20% 4.972.300
15/01/2014 50,65 50,67 50,07 50,11 -0,97% 1,18% 4.728.400
14/01/2014 49,94 50,88 49,63 50,60 +1,55% 2,50% 6.610.800